To investigate the clinical effect of modified radical mastectomy and axillary lymph node preservation for breast cancer.

A total of 61 patients with negative early breast cancer treated surgical treatment between April 2017 and April 2019.The patients were divided into two groups according to different surgical methods: 35 patients in the improved group received improved radical mastectomy for breast cancer, and 26 patients in the axillary-preserving group received axillary lymph node preserving mastectomy for breast cancer. Clinical data analysis using the statistical software SPSS 24.0, perioperative indicators and QLQ-BR23 score measurement data used (±s) said, comparison between groups use independent sample t test; The statistical data of postoperative complications were tested by χ² test. The disease-free survival curve was ploted by Kaplan-Meier method, and the difference in survival rate was analyzed by Log-rank test. P<0.05 was considered statistically significant.

The operative time, intraoperative blood loss, extubation time and drainage volume in axil-preserving group were less than those in improved group (P<0.05). The complication rate of improved group (34.2%) was significantly higher than that of axillary protection group (11.5%) (P<0.05). Comparison of The QLQ-BR23 scores one year after operation showed that the axillary preservation group was significantly better than the preservation group in body shape assessment, side effects and upper limb symptoms scores, with statistically significant differences (P<0.05). The follow-up period ranged from 14 ~ 38 months, and the median follow-up time was 27 months. There was no significant difference in disease-free survival rate between the two groups (P>0.05).

Axillary preservation radical mastectomy for sentinel lymph node negative patients with early-stage breast cancer can reduce the incidence of postoperative complications, improve the quality of life, and has no significant impact on the long-term prognosis, which is worthy of clinical application.